Opportunities

Company with sleep apnea asset seeks development partner

/in , /by

First sleep apnea oral therapy available for co-development. Phase II study completed with positive results. Company has completed first round of financing raising $40 million. Market is highly unsatisfied. Strong IP protection through 2039.

Read more

Schizophrenia asset available for in-licensing

/in , /by

505(b)(2) product for the treatment of schizophrenia available for in-licensing. Multiple markets available including the US. NDA filed in the US in 2019. Approval expected in 2021.

Read more

Questions? Feel free to contact us!

Call (615) 887-3847

We appreciate your interest!  Please get in touch and we will contact you directly.

Services and Partnership Opportunities

  • Pharmaceutical BD&L
  • Pharma BD&L
  • Pharmaceutical business development
  • ANDAs for sale
  • ANDA licensing
  • Pharmaceutical in-licensing
  • Pharmaceutical out-licensing
  • 505(b)(2) for sale
  • Pharma in-licensing
  • Pharma out-licensing
  • Oncology company for sale
  • Oncology sales force
  • Pharma distribution deals
  • Branded generics for sale
  • Pharmaceutical partnering companies
  • Pharmaceutical development deals
  • Pharma commercialization consulting
  • Head and neck cancer assets available for licensing
  • Pharmaceutical deal arrangers
  • Pharma manufacturing facilities finders
  • Pharmaceutical authorized generic products available

 

Commercial Healthcare Partners

DISCLAIMER

The information contained in this website is for general information purposes only. The information is provided by Commercial Healthcare Partners and while we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

About | Services| Contact | Privacy Policy